Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients

Clinical Cancer Research

Volumn 2, Issue 10, 1996, Pages 1699-1704

  Chambers, Setsuko K ^a   Davis, Carol A ^a   Chambers, Joseph T ^a   Schwartz, Peter E ^a   Lorber, Marc I ^a   Handschumacher, Robert E ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CYCLOSPORIN A;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GYNECOLOGIC CANCER; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

ANEMIA; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CARBOPLATIN; CYCLOSPORINE; FEMALE; HUMANS; HYPERTENSION; HYPOTENSION; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; LEUKOPENIA; NAUSEA; NEUTROPENIA; OVARIAN NEOPLASMS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0029859820     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Sutton, G. P , Stehman, F. B., Einhorn, L. H., Roth, L. M., Blessing, J. A., and Ehrlich, C. E. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J. Clin. Oncol., 7: 223-229, 1989.
2. Houghton, P. J., and Kaye, S. B. Multidrug resistance is not an important factor in therapeutic outcome in human malignancies. J. Natl. Inst. Health Res., 6: 55-61, 1994.
3. Rubin, S. C., Finstad, C. L , Hoskins, W. J., Saigo, P. E., Provencher, D. M., Federici, M. G., Hakes, T. B., Markman, M., Reichman, B. S., Lloyd, K. O., and Lewis, J. L., Jr. Expression of P-glycoprotein in epithelial ovarian cancer: evaluation as a marker of multidrug resistance. Am. J. Obstet. Gynecol., 163: 69-73, 1990.
4. van der Zee, A. G. J., Hollema, H., Suurmeijer, A. J. H., Krans, M., Sluiter, W. J., Willemse, P. H. B., Aalders, J. G., and de Vries, E. G. E. Value of P-glycoprotein, glutathione 5-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J. Clin. Oncol., 13: 70-78, 1995.
5. Horwitz, S. B., Lothstem, L., Manfredi, J. J., Mellado, W., Parness, J., Roy, S. N., Schiff, P. B., Sorbara, L., and Zeheb, R. Taxol: mechanisms of action and resistance. Ann. N.Y. Acad. Sci., 466: 733-744, 1986.
6. Lum, B. L , Kaubisch, S., Yahanda, A. M., Jew, L., Ehsan, M. E , Brophy, N. A , Halsey, J., Gosland, M. P., and Sikic, B. I. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J. Clin. Oncol., 10: 1635-1642, 1992.
7. Samuels, B. L., Mick, R., Vogelzang, N. J., Williams, S. F., Schilsky, R. L , Safa, A. R., O'Brien, S. M., and Ratain, M. J. Modulation of vinblastine resistance with cyclosporine: a phase I study. Clin. Pharmacol. Ther, 54: 421-429, 1993.
8. Bartlett, N. L., Lum, B. L., Fisher, G. A., Brophy, N. A., Ehsan, M. N., Halsey, J., and Sikic, B. I. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J. Clin. Oncol , 12: 835-842, 1994.
9. Erlichman, C., Moore, M., Thiessen, J. J., Kerr, I. G., Walker, S., Goodman, P., Bjarnason, G., DeAngelis, C., and Bunting, P. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res., 53: 4837-4842, 1993.
10. Sonneveld, P., Durie, B. G. M., Lokhorst, H. M., Marie, J-P., Solbu, G., Suciu, S., Zittoun, R., Lowenberg, B., and Nooter, K Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet, 340: 255-259, 1992.
11. Yahanda, A. M., Adler, K. M., Fisher, G. A., Brophy, N. A., Halsey, J , Hardy, R. I., Gosland, M. P., Lum, B. L., and Sikic, B. I. Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J. Clin. Oncol., 10: 1624-1634, 1992.
12. Chambers, S. K., Hait, W. N., Kacinski, B. M., Keyes, S. R., and Handschumacher, R. E. Enhancement of anthracycline growth inhibition in parent and multidrug-resistant Chinese hamster ovary cells by cyclosporin A and its analogues. Cancer Res., 49: 6275-6279, 1989.
13. Meador, J., Sweet, P., Stupeck, M., Wetzel, M., Murray, S., Gupta, S., and Slater, L. Enhancement by cyclosporin A of daunorubicin efficacy in Ehrlich ascites carcinoma and murine hepatoma 129. Cancer Res., 47: 6216-6219, 1987.
14. Slater, L. M., Sweet, P., Stupecky, M., Wetzel, M. W., and Gupta, S. Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma. Br. J. Cancer, 54: 235-238, 1986.
15. Kashani-Sabet, M., Wang, W., and Scanlon, K. J. Cyclosporin A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells. J. Biol. Chem., 265: 11285-11288, 1990.
16. Mutch, D. G., Herzog, T. J., Chen, C. A., and Collins, J. L. The effects of cyclosporin A on the lysis of ovarian cancer cells by cisplatin or Adriamycin. Gynecol. Oncol., 47: 28-33, 1992.
17. Scanlon, K. J., Wang, W., and Han, H. Cyclosporin A suppresses cisplatin-induced oncogene expression in human cancer cells. Cancer Treat. Rev., 17 (Suppl. A): 27-35, 1990.
18. Morgan, R. J., Margolin, K., Raschko, J., Akman, S., Leong, L , Somlo, G., Scanlon, K., Ahn, C., Carroll, M., and Doroshow, J. H. Phase I trial of carboplatin and infusional cyclosporine in advanced malignancy. J. Clin. Oncol., 13: 2238-2246, 1995.
19. Stratton, J. A., and DiSaia, P. J. Reversal of cisplatinum resistance by cyclosporin A in xenografts of fresh human ovarian carcinoma (Abstract). Proc. Am. Assoc. Cancer Res,. 29: 479, 1988.
20. Manetta, A., Boyle, J., Berman, M. L., DiSaia, P. J., Lentz, S., Liao, S. Y., Mutch, D., and Slater, L. Cyclosporin enhancement of cisplatin chemotherapy in patients with refractory gynecologic cancer. Cancer (Phila.), 73: 196-199, 1994.
21. Tosetti, F., Rocco, M., Fulco, R. A., Chiara, S., Bruzzone, M., Campora, E., and Esposito, M. Serial determination of platinum, protein content and free sulfhydryl levels in plasma of patients treated with cisplatin or carboplatin. Anticancer Res., 8: 381-386, 1988.
22. Kahan, B. D., and Grevel, J. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation, 46: 631-644, 1988
23. Kahan, B. D. Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters Transplantation, 40: 457-476, 1985.
24. Critical issues in cyclosporine monitoring: report of the task force on cyclosporine monitoring. Clin. Chem., 33: 1269-1288, 1987.
25. Lum, B. L., Fisher, G. A., Brophy, N. A., Yahanda, A. M., Adler, K. M., Kaubisch, S., Halsey, J., and Sikic, B. I. Clinical trials of modulation of multidrug resistance. Cancer (Phila.), 72 (Suppl.): 3502-3514, 1993.
26. Ozols, R. F., Cunnion, R. E., Klecker, R. W., Jr., Hamilton, T. C., Ostchega, Y., Parrillo, J. E., and Young, R. C. Verapamil and Adriamycin in the treatment of drug-resistant ovarian cancer patients. J. Clin. Oncol., 5. 641-647, 1987.
27. Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E , McFadden, E. T., and Carbone, P. P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol., 5: 649-655, 1982.
28. Cockburn, I. Cyclosporin-A: a clinical evaluation of drug interactions. Transplant. Proc., 18 (Suppl. 5): 50-55, 1986.
29. Calvert, A. H., Newell, D. R., Gumbrell, L. A., O'Reilly, S., Burnell, M., Boxall, F. E., Siddik, Z. H., Judson, I. R., Gore, M. E., and Wiltshaw, E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol., 7: 1748-1756, 1989.
30. Chambers, J. T., Chambers, S. K., and Schwartz, P. E. Correlation between measured creatinine clearance and calculated creatinine in ovarian cancer patients. Gynecol. Oncol., 36: 66-68, 1990.
31. Ptachcinski, R. J., Venkataramanan, R., Rosenthal, J. T., Burckhart, G. J., Taylor, R. J., and Hakala, T. R. Cyclosporine kinetics in renal transplantation. Clin. Pharmacol. Ther , 38: 296-300, 1985.
32. Chatelut, E., Canal, P., Brunner, V., Chevreau, C., Pujol, A., Boneu, A., Roche, H., Houin, G., and Bugat, R. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J. Natl. Cancer Inst., 87 573-580, 1995.
33. Markman, M., and Hoskins, W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population (Editorial). J. Clin. Oncol., 10: 513-514, 1992.
34. Morgan, R., Doroshow, J. H., Egorin, M., Kearns, C., Zuhowski, E., Carroll, M., Rincon, A., Coluzzi, P., Hamasaki, V., Tetef, M., Raschko, J., Leong, L., Margolin, K., Somlo, G., Shibata, S., Ahn, C., Akman, S., Yen, Y., and Chow, W. Unexpectedly severe myelosuppression of carboplatin (CBDCA)/Taxol (T)/cyclosporine (CsA) combination chemotherapy unrelated to sequence (seq) of drug administration or pharmacokinetic (PK) alterations (Abstract). Proc. Am. Soc Clin. Oncol., 14: 464, 1995.
35. Jodrell D. I., Egorin M. J., Canetta R. M., Langenberg P., Goldbloom E. P., Burroughs J. N, Goodlow J. L., Tan S., and Wiltshaw E. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol, 10: 520-528, 1992.